High throughput DAR determination of brentuximab vedotin (Adcetris®) by reducing the analysis time
contributed by YMC |
Drug-to-antibody ratios (DAR) of antibody-drug-conjugates (ADCs) such as brentuximab vedotin is important for their therapeutic efficacy and pharmacokinetics. Therefore, control of DAR is a key factor for ADC quality control. Given that, it is important for QC purposes to obtain a satisfying resolution of all DARs and the resulting average ratio whilst performing the separation in the shortest time.
Read the full article now
Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE and always will be!
Login
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Analytical Scientist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.
